While Medicare has recently (since 2023) expanded continuous glucose monitoring access by removing multiple daily insulin as a requirement and including CGM coverage for adults using once-daily insulin and those with clinically significant hypoglycemia, coverage for individuals with T2DM remains very limited [13, 14]. The gene discussed is INS; the disease is type 2 diabetes mellitus.